Skip to main content
SpringerLink
Log in

Reasons for new patient warfarin referrals to an anticoagulant management service in 2019: a single institution experience

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Craig TJ, Wann LS, Hugh C et al (2019) 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. J Am Coll Cardiol 74(1):104–132

    Article  Google Scholar 

  2. Kearon C et al (2016) Antithrombotic therapy for VTE disease. Chest 149(2):315–352. https://doi.org/10.1016/j.chest.2015.11.026

    Article  PubMed  Google Scholar 

  3. Ting C, Fanikos C, Fatani N, Buckley LF, Fanikos J (2019) Use of direct oral anticoagulants among patients with limited income and resources. J Am Coll Cardiol 5(4):526–528. https://doi.org/10.1016/j.jacc.2018.11.024

    Article  Google Scholar 

  4. Eikelboom JW, Connolly SJ, Brueckmann M et al (2013) Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 369:1206–1214

    Article  CAS  PubMed  Google Scholar 

  5. Martin A, Moayedifar R, Wieselthaler G et al (2017) Increased thromboembolic events with dabigatran compared with vitamin K antagonism in left ventricular assist device patients. Circ Heart Failure. https://doi.org/10.1161/CIRCHEARTFAILURE.116.003709

    Article  PubMed  Google Scholar 

  6. Pengo V et al (2018) Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 132(13):1365–1371

    Article  CAS  PubMed  Google Scholar 

  7. Robinson AA, Trankle CR, Eubanks G et al (2020) Off-label use of direct oral anticoagulants compared with warfarin for left ventricular thrombi. JAMA Cardiol 5:685

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

There was no financial support for the research, authorship, and/or publication of this article.

Author information

Authors and Affiliations

  1. Department of Pharmacy Services, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA, 02115, USA

    Katelyn W. Sylvester, Caroline Wagner, Andrea Lewin & John Fanikos

  2. Bouvé College of Health Sciences, Northeastern University, 360 Huntington Ave, Boston, MA, 02115, USA

    Caroline Wagner

  3. Division of Cardiovascular Medicine, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA, 02115, USA

    Samuel Z. Goldhaber

  4. Division of Hematology, Brigham and Women’s Hospital, 45 Francis Street, Boston, MA, 02115, USA

    Jean M. Connors

Authors
  1. Katelyn W. Sylvester
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Caroline Wagner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrea Lewin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John Fanikos
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Samuel Z. Goldhaber
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jean M. Connors
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

KWS and CW devised the project, wrote the manuscript and provided data for Figure 1. KWS, CW, AL, JF, SZG and JMC contributed to the study design, reviewed and edited the final manuscript.

Corresponding author

Correspondence to Jean M. Connors.

Ethics declarations

Conflict of interest

Jean M. Connors is a consultant for Abbott, Bristol Myers Squibb, eXIthera, and Pfizer. She has served on a scientific advisory board for Bristol Myers Squibb, eXIthera, and Portola. She has served on a data safety monitoring board for Unum Therapeutics. Katelyn Sylvester has severed as a consultant for Portola Pharmaceuticals, Inc. John Fanikos is a consultant for Portola Pharmaceuticals, Inc and has served as an investigator for Boehringer-Ingelheim. Samuel Goldhaber is a consultant for Bayer and Boehringer-Ingelheim. He has received research support from Boehringer-Ingelheim, Bristol Myers Squibb, BTG EKOS, Daiichi Sankyo, Janssen, the US National Heart Lung and Blood Institute, and the Thrombosis Research Institute. The remaining authors have no conflict of interest to disclose.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sylvester, K.W., Wagner, C., Lewin, A. et al. Reasons for new patient warfarin referrals to an anticoagulant management service in 2019: a single institution experience. J Thromb Thrombolysis 52, 158–160 (2021). https://doi.org/10.1007/s11239-020-02293-3

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-020-02293-3

Search

Navigation